These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19709151)

  • 21. Cost-effectiveness of insulin analogues for diabetes mellitus.
    Cameron CG; Bennett HA
    CMAJ; 2009 Feb; 180(4):400-7. PubMed ID: 19221353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group.
    Gale EA
    Diabet Med; 2000 Mar; 17(3):209-14. PubMed ID: 10784225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK.
    Roze S; Valentine WJ; Zakrzewska KE; Palmer AJ
    Diabet Med; 2005 Sep; 22(9):1239-45. PubMed ID: 16108855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
    Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
    Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries.
    Gschwend MH; Aagren M; Valentine WJ
    J Med Econ; 2009 Jun; 12(2):114-23. PubMed ID: 19545216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes. Pharmacoeconomic analysis of cost-effectiveness].
    Costa Pinel B; Belmonte Serrano M; Páez Vives F; Sabaté Obiol A; Estopá Sánchez A; Borrás Borrás J
    Rev Clin Esp; 2001 Aug; 201(8):448-54. PubMed ID: 11599156
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark].
    Palmer AJ; Lammert M; Hermansen K
    Ugeskr Laeger; 2008 Apr; 170(15):1250-4. PubMed ID: 18433583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M; White J; Lee CH; Palmer JL; Smith-Palmer J; Fakhoury W; Valentine WJ
    J Med Econ; 2008; 11(4):651-70. PubMed ID: 19450074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting.
    Russell-Jones D; Heller SR; Buchs S; Sandberg A; Valentine WJ; Hunt B
    Diabetes Obes Metab; 2017 Dec; 19(12):1773-1780. PubMed ID: 28573681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does insulin lispro preserve the physiological defences to hypoglycaemia during intensive insulin therapy with a conventional basal bolus regimen?
    Heller SR; Amiel SA; Evans ML; Kong MF; Macdonald IA; Peacey SR
    Diabetes Obes Metab; 2002 Mar; 4(2):106-12. PubMed ID: 11940107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin glulisine.
    Robinson DM; Wellington K
    Drugs; 2006; 66(6):861-9. PubMed ID: 16706558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
    Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
    Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.
    Valentine WJ; Jendle J; Saraheimo M; Thorsteinsson B; Pollock RF; Lammert M
    Diabet Med; 2012 Mar; 29(3):303-12. PubMed ID: 21951030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes.
    Roze S; Saunders R; Brandt AS; de Portu S; Papo NL; Jendle J
    Diabet Med; 2015 May; 32(5):618-26. PubMed ID: 25483869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health economics analysis of insulin aspart vs. regular human insulin in type 2 diabetes patients, based on observational real life evidence from general practices in Germany.
    Liebl A; Seitz L; Palmer AJ
    Exp Clin Endocrinol Diabetes; 2014 Oct; 122(9):517-22. PubMed ID: 25148263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-effectiveness of the Dose Adjustment for Normal Eating (DAFNE) structured education programme: an update using the Sheffield Type 1 Diabetes Policy Model.
    Kruger J; Brennan A; Thokala P; Basarir H; Jacques R; Elliott J; Heller S; Speight J
    Diabet Med; 2013 Oct; 30(10):1236-44. PubMed ID: 23815547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH.
    Valentine WJ; Palmer AJ; Erny-Albrecht KM; Ray JA; Cobden D; Foos V; Lurati FM; Roze S
    Adv Ther; 2006; 23(2):191-207. PubMed ID: 16751153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis.
    Davey P; Grainger D; MacMillan J; Rajan N; Aristides M; Gliksman M
    Clin Ther; 1997; 19(4):656-74. PubMed ID: 9377611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.